Point72 Asset Management
TRVI icon

Point72 Asset Management’s Trevi Therapeutics TRVI Stock Holding History

Point72 Asset Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,000,000
Closed -$12.5M – 4521
2025
Q4 		$12.5M Buy
1,000,000
+58,071
+6% +$671K 0.01% 1216
2025
Q3 		$8.62M Sell
941,929
-786,747
-46% -$5.9M 0.01% 850
2025
Q2 		$9.46M Sell
1,728,676
-639,329
-27% -$3.98M 0.02% 758
2025
Q1 		$14.9M Sell
2,368,005
-1,782,232
-43% -$8.5M 0.03% 531
2024
Q4 		$17.1M Buy
+4,150,237
New +$13.3M 0.04% 509

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Point72 Asset Management's TRVI Position: Q1 2026 in Review

Point72 Asset Management sold out of Trevi Therapeutics (TRVI) in Q1 2026, closing a stake of 1,000,000 shares — an estimated $12.5M sold.

Point72 Asset Management first reported a position in TRVI in Q4 2024 and held it in 5 quarters. The position peaked at $17.1M in Q4 2024. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Point72 Asset Management reported no remaining Trevi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 1,000,000 Trevi Therapeutics shares in Q1 2026, an estimated $12.5M.
  • Point72 Asset Management first reported a position in Trevi Therapeutics in Q4 2024 and held it in 5 quarters.
  • Point72 Asset Management's Trevi Therapeutics position peaked at $17.1M in Q4 2024.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.